A new cancer immunosuppression target: Indoleamine 2,3-dioxygenase (IDO). A review of the IDO mechanism, inhibition and therapeutic applications

Drugs of the Future

Volumn 30, Issue 9, 2005, Pages 897-909

  Malachowski, William P ^a   Metz, Richard ^b   Prendergast, George C ^c   Muller, Alexander J ^c,d  

^a BRYN MAWR COLLEGE   (United States)

^b Department of Research and Development   (United States)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BETA CARBOLINE DERIVATIVE; CYTOTOXIC AGENT; INDOLE DERIVATIVE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; KYNURENINE; OXETANE DERIVATIVE; PACLITAXEL; TRYPTOPHAN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE;

EID: 30544455181     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.09.918200     Document Type: Review

References (66)

1. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002, 3(11): 991-8.
2. Melief, C.J., Toes, R.E., Medema, J.P., van der Burg, S.H., Ossendorp, F., Offringa, R. Strategies for immunotherapy of cancer. Adv Immunol 2000, 75: 235-82.
3. Finn, O.J. Cancer vaccines: Between the idea and the reality. Nat Rev Immunol 2003, 3(8): 630-41.
4. Gilboa, E. The promise of cancer vaccines. Nat Rev Cancer 2004, 4(5): 401-11.
5. O'Neill, D.W., Adams, S., Bhardwaj, N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004, 104(8): 2235-46.
6. Figdor, C.G., de Vries, I.J., Lesterhuis, W.J., Melief, C.J. Dendritic cell immunotherapy: Mapping the way. Nat Med 2004, 10(5): 475-80.
7. Rosenberg, S.A., Packard, B.S., Aebersold, P.M. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New Engl J Med 1988, 319(25): 1676-80.
8. Dudley, M.E., Wunderlich, J.R., Robbins, P.F. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298(5594): 850-4.
9. Zou, X., Rudchenko, S., Wong, K., Calame, K. Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1, and cyclin-dependent kinases. Genes Dev 1997, 11: 654-62.
10. Sono, M. The roles of superoxide anion and methylene blue in the reductive activation of indoleamine 2,3-dioxygenase by ascorbic acid or by xanthine oxidase-hypoxanthine. J Biol Chem 1989, 264(3): 1616-22.
11. Sono, M., Roach, M.P., Coulter, E.D., Dawson, J.H. Heme-containing oxygenases. Chem Rev 1996, 96(7): 2841-88.
12. Sono, M., Taniguchi, T., Watanabe, Y., Hayaishi, O. Indoleamine 2,3-dioxygenase. Equilibrium studies of the tryptophan binding to the ferric, ferrous, and CO-bound enzymes. J Biol Chem 1980, 255(4): 1339-45.
13. Nakagawa, M., Watanabe, H., Kodato, S. et al. A valid model for the mechanism of oxidation of tryptophan to formylkynurenine-25 years later. Proc Natl Acad Sci USA 1977, 74: 4730-3.
14. Witkop, B., Patrick, J.B. On the mechanism of oxidation. I. A new type of peroxide rearrangement catalyzed by acid. J Am Chem Soc 1951, 73: 2196-200.
15. Hamilton, G.A. Mechanisms of two- and four-electron oxidations catalyzed by some metalloenzymes. Adv Enzymol 1969, 32: 55-96.
16. Cady, S.G., Sono, M. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL- alanine (the oxygen analog of tryptophan), and beta-3-benzo(b)thienyl-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 1991, 291: 326-33.
17. Terentis, A.C., Thomas, S.R., Takikawa, O. et al. The heme environment of recombinant human indoleamine 2,3-dioxygenase. Structural properties and substrate-ligand interactions. J Biol Chem 2002, 277(18): 15788-94.
18. Fleming, I. Group transfer reactions. In: Pericyclic Reactions. S.G. Davies (Ed.). Oxford University Press: Oxford 1999, 84-7.
19. Littlejohn, T.K., Takikawa, O., Truscott, R.J., Walker, M.J. Asp274 and His346 are essential for heme binding and catalytic function of human indoleamine 2,3-dioxygenase. J Biol Chem 2003, 278(32): 29525-31.
20. Leeds, J.M., Brown, P.J., McGeehan, G.M., Brown, F.K., Wiseman, J.S. Isotope effects and alternative substrate reactivities for tryptophan 2,3-dioxygenase. J Biol Chem 1993, 268(24): 17781-6.
21. Hamilton, G.A. In: Molecular Mechanisms of Oxygen Activation. O. Hayaishi (Ed.). Academic Press: New York 1974, 405-51.
22. Muto, S., Bruice, T.C. Differentiation between Criegee rearrangement and dioxetane rearrangement mechanisms for the decomposition of alpha-, beta-unsaturated hydroperoxides. J Am Chem Soc 1980, 102: 7379-81.
23. Fraser, M.S., Hamilton, G.A. Models for oxygenases that catalyze the cleavage of carbon-carbon bonds: Kinetics and mechanism of the decomposition of 2,3-dimethyl-3-peroxyindolenines in aqueous solution. J Am Chem Soc 1982, 104: 4203-11.
24. Hirata, F., Hayaishi, O. New degradative routes of 5-hydroxytryptophan and serotonin by intestinal tryptophan 2,3-dioxygenase. Biochem Biophys Res Commun 1972, 47(5): 1112-9.
25. Hirata, F., Hayaishi, O., Tokuyama, T., Seno, S. In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem 1974, 249(4): 1311-3.
26. Shimizu, T., Nomiyama, S., Hirata, F., Hayaishi, O. Indoleamine 2,3-dioxygenase. Purification and some properties. J Biol Chem 1978, 253(13): 4700-6.
27. Sono, M., Dawson, J.H. Extensive studies of the heme coordination structure of indoleamine 2,3-dioxygenase and of tryptophan binding with magnetic and natural circular dichroism and electron paramagnetic resonance spectroscopy. Biochim Biophys Acta 1984, 789(2): 170-87.
28. Munn, D.H., Zhou, M., Attwood, J.T. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281: 1191-3.
29. Peterson, A.C., Migawa, M.T., Martin, M.M. et al. Evaluation of functionalized tryptophan derivatives and related compounds as competitive inhibitors of indoleamine 2,3-dioxygenase. Med Chem Res 1994, 3: 531-44.
30. Sono, M. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 2. Evidence for the existence of another binding site in the enzyme for indole derivative effectors. Biochemistry 1989, 28(13): 5400-7.
31. Mellor, A.L., Chandler, P., Baban, B. et al. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004, 16(10): 1391-401.
32. Munn, D.H., Sharma, M.D., Lee, J.R. et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002, 297(5588): 1867-70.
33. Munn, D.H., Sharma, M.D., Hou, D. et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004, 114(2): 280-90.
34. Hammett, L. P. Physical Organic Chemistry; Reaction Rates, Equilibria and Mechanisms. 2nd Edition. McGraw-Hill: New York 1970.
35. Chu, K.C. The quantitative analysis of structure-activity relationships. In: The Basis of Medicinal Chemistry. M.E. Wolff (Ed.). Wiley-Interscience: New York 1980, 393-418.
36. Martin, Y.C. Quantitative Drug Design. Marcel Dekker: New York 1978.
37. Southan, M.D., Truscott, R.J.W., Jamie, J.F. et al. Structural requirements of the competitive binding site of recombinant human indoleamine 2,3-dioxygenase. Med Chem Res 1996, 6: 343-52.
38. Eguchi, N., Watanabe, Y., Kawanishi, K., Hashimoto, Y., Hayaishi, O. Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives. Arch Biochem Biophys 1984, 232(2): 602-9.
39. Muller, A.J., Duhadaway, J.B., Donover, P.S., Sutanto-Ward, E., Prendergast, G.G. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005, 11(3): 312-9.
40. Salter, M., Hazelwood, R., Pogson, C.I., Iyer, R., Madge, D.J. The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat. Biochem Pharmacol 1995, 49(10): 1435-42.
41. Watanabe, Y., Fujiwara, M., Hayaishi, O. 2,5-Dihydro-L-phenylalanine: A competitive inhibitor of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 1978, 85(1): 273-9.
42. Thomas, S.R., Salahifar, H., Mashima, R., Hunt, N.H., Richardson, D.R., Stocker, R. Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: Posttranslational regulation by pyrrolidine dithiocarbamate. J Immunol 2001, 166(10): 6332-40.
43. Sono, M., Cady, S.G. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands. Biochemistry 1989, 28(13): 5392-9.
44. Peterson, A.C., La Loggia, A.J., Hamaker, L.K. et al. Evaluation of substituted beta-carbolines as noncompetitive indoleamine 2,3-dioxygenase inhibitors. Med Chem Res 1993, 4: 473-82.
45. Tenen, S.S., Hirsch, J.D. β-Carboline-3-carboxylic acid ethyl ester antagonizes diazepam activity. Nature 1980, 288(5791): 609-10.
46. Braestrup, C., Nielsen, M., Olsen, C.E. Urinary and brain beta-carboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors. Proc Natl Acad Sci USA 1980, 77(4): 2288-92.
47. Lippke, K.P., Schunack, W.G., Wenning, W., Muller, W.E. β-Carbolines as benzodiazepine receptor ligands. 1. Synthesis and benzodiazepine receptor interaction of esters of β-carboline-3-carboxylic acid. J Med Chem 1983, 26(4): 499-503.
48. Guzman, F., Cain, M., Larscheid, P. et al. Biomimetic approach to potential benzodiazepine receptor agonists and antagonists. J Med Chem 1984, 27(5): 564-70.
49. Higuchi, K., Hayaishi, O. Enzymic formation of D-kynurenine from D-tryptophan. Arch Biochem Biophys 1967, 120(2): 397-403.
50. Mellor, A.L., Munn, D.H. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4(10): 762-74.
51. Mellor, A.L., Sivakumar, J., Chandler, P. et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001, 2(1): 64-8.
52. Boyland, E., Williams, D.C. The metabolism of tryptophan. 2. The metabolism of tryptophan in patients suffering from cancer of the bladder. Biochem J 1956, 64(3): 578-82.
53. Ozaki, Y., Edelstein, M.P., Duch, D.S. Induction of indoleamine 2,3-dioxygenase: A mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci USA 1988, 85(4): 1242-6.
54. Sakamuro, D., Elliott, K.J., Wechsler-Reya, R., Prendergast, G.G. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet 1996, 14(1): 69-77.
55. Elliott, K., Sakamuro, D., Basu, A. et al. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene 1999, 18(24): 3564-73.
56. Muller, A.J., Baker, J.F., DuHadaway, J.B. et al. Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol Cell Biol 2003, 23(12): 4295-306.
57. Ge, K., Duhadaway, J., Sakamuro, D., Wechsler-Reya, R., Reynolds, C., Prendergast, G.C. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity, Int J Cancer 2000, 85(3): 376-83.
58. Piao, Z., Lee, K.S., Kim, H., Perucho, M., Malkhosyan, S. Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis. Genes Chromosomes Cancer 2001, 30(2): 113-22.
59. Tanner, M.M., Karhu, R.A., Nupponen, N.N. et al. Genetic aberrations in hypodiploid breast cancer: Frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. Am J Pathol 1998, 153(1): 191-9.
60. Kerangueven, R, Noguchi, T., Coulier, F. et al. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res 1997, 57: 5469-74.
61. Tirkkonen, M., Johannsson, O., Agnarsson, B.A. et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997, 57(7): 1222-7.
62. Ge, K., Minhas, F., DuHadaway, J. et al. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma, Int J Cancer 2000, 86(2): 155-61.
63. DuHadaway, J.B., Lynch, F.J., Brisbay, S. et al. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: Diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem 2003, 88(3): 635-42.
64. Friberg, M., Jennings, R., Alsarraj, M. et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection, Int J Cancer 2002, 101(2): 151-5.
65. Uyttenhove, C., Pilotte, L., Theate, I. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9(10): 1269-74.
66. Lake, R.A., Robinson, B.W. Opinion: Immunotherapy and chemotherapy - A practical partnership. Nat Rev Cancer 2005, 5(5): 397-405.